This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): meropenem, Meropen (Japan), MEM
Description: MERREM is a carbapenem antibiotic.
Carbapenems are a class of beta-lactam antibiotics with a broad spectrum of antibacterial activity, and have a structure which renders them highly resistant to beta-lactamases. Members of this class exhibit good activity against methicillin-sensitive Staphylococcus aureus, streptococci, anaerobes, enteric Gram-(-) rods (including strains that produce extended spectrum beta lactamases), Pseudomonas, and Acinetobacter. Moderate activity is observed against enterococci, and relatively modest activity against methicillin-resistant S. aurus and penicillin-resistant streptococci.
AstraZeneca and Sumitomo
In 1990, AstraZeneca licensed Meropenum from Sumitomo Pharmaceuticals.
Cubist and AstraZeneca
In July 2008, Cubist Pharmaceuticals announced that it has signed an exclusive agreement with AstraZeneca to promote and provide other support in the United States for MERREM I.V. Cubist will promote and support MERREM I.V. using its existing U.S. acute care sales and medical affairs organizations. AstraZeneca will continue to provide marketing and commercial support for MERREM I.V. The agreement, effective July 1, 2008, establishes a baseline of $20 million annual revenue to Cubist that will be adjusted based on actual MERREM I.V. sales. Other terms of the agreement, including the performance incentives, are confidential. This agreement expired on June 30, 2010.
AstraZeneca and Pfizer
In August 2016, AstraZeneca announced that it has entered into an agreement with Pfizer to sell the commercialisation and development...See full deal structure in Biomedtracker
Partners: Sumitomo Dainippon Pharma Co., Ltd.
Pink Sheet AstraZeneca Merrem I.V. sNDA
Additional information available to subscribers only: